AbCellera Biologics (ABCL) Amortization of Deferred Charges (2020 - 2026)

AbCellera Biologics' Amortization of Deferred Charges history runs 7 years deep, the most recent figure standing at $1.8 million for Q1 2026.

• Quarterly Amortization of Deferred Charges rose 42.62% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.2 million (up 30.76% YoY) and the FY2025 annual result came in at $6.6 million, up 8.15% from the prior year.
• Amortization of Deferred Charges was $1.8 million for Q1 2026 at AbCellera Biologics, up from $1.8 million in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $2.0 million in Q3 2025 and bottomed at $976000.0 in Q1 2022.
• A 5-year average of $1.6 million and a median of $1.6 million in 2022 frame the typical range for Amortization of Deferred Charges.
• Annual changes were most pronounced in 2022 — Amortization of Deferred Charges jumped 189.46% — and 2025, when it tumbled 33.71%.
• AbCellera Biologics' Amortization of Deferred Charges stood at $1.6 million in 2022, then changed by 0.0% to $1.6 million in 2023, then decreased by 15.07% to $1.3 million in 2024, then soared by 34.51% to $1.8 million in 2025, then climbed by 1.11% to $1.8 million in 2026.
• Business Quant data shows ABCL's Amortization of Deferred Charges at $1.8 million in Q1 2026, $1.8 million in Q4 2025, and $2.0 million in Q3 2025.